Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies

In the PATHWAY-2 study of resistant hypertension, spironolactone reduced blood pressure substantially more than conventional antihypertensive drugs. We did three substudies to assess the mechanisms underlying this superiority and the pathogenesis of resistant hypertension. PATHWAY-2 was a randomised...

Celý popis

Podrobná bibliografia

Vydané v:	The lancet. Diabetes & endocrinology Ročník 6; číslo 6; s. 464
Hlavní autori:	Williams, Bryan, MacDonald, Thomas M, Morant, Steve V, Webb, David J, Sever, Peter, McInnes, Gordon T, Ford, Ian, Cruickshank, J Kennedy, Caulfield, Mark J, Padmanabhan, Sandosh, Mackenzie, Isla S, Salsbury, Jackie, Brown, Morris J
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	England 01.06.2018
Predmet:	Aldosterone - metabolism Amiloride - therapeutic use Antihypertensive Agents - therapeutic use Bisoprolol - therapeutic use Blood Pressure - drug effects Doxazosin - therapeutic use Female Hemodynamics - drug effects Humans Hypertension - drug therapy Male Middle Aged Randomized Controlled Trials as Topic Spironolactone - therapeutic use
ISSN:	2213-8595, 2213-8595
On-line prístup:	Zistit podrobnosti o prístupe
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!